We have used our unique stem cell technologies to develop cell-based therapies for significant disease conditions where the cells can be readily administered “off-the-shelf” to any eligible patient without the need for additional drug treatments.
To view the 2019 preliminary results presentation please click here.
Our human retinal progenitor cell line (hRPC) is being developed for the treatment of retinal diseases. Clinical development of hRPC for retinitis pigmentosa, a blindness-causing disease of the retina, is progressing in the US and we have the potential to expand our hRPC platform to target a further retinal diseases such as cone-rod dystrophy.
Our immortalised neural progenitor cell line (CTX) is being developed as a therapy for the treatment of patients left disabled by a stroke. We have announced positive Phase II data with this therapeutic candidate and a Phase IIb trial in patients who are living with disability post-stroke is currently progressing.
We are also progressing development of our exosomes platform, focusing on its use as a novel vector for delivering third party drugs. Exosomes are nano-sized particles that facilitate the communication between cells through the transfer of biologically active molecules such as proteins and nucleic acids (RNA and DNA). Large numbers of exosomes are secreted into the culture media during the expansion of our stem cells. Following purification, these natural delivery vehicles can be modified or ‘loaded’ with complex, hard-to-deliver therapeutic agents to specific areas of the body.
Our principal strategy is to gain clinical validation for our cell therapy programmes via well-designed clinical trials in well-regulated territories.
Ultimately, we expect to realise value for our technologies and therapeutic programmes via out-license to commercial development partners at the appropriate points in their development. We have recently partnered with Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd. for the development, manufacture and commercialisation of our hRPC and CTX platforms in the People’s Republic of China.
ReNeuron has also signed a collaboration agreement with a US-based biopharmaceutical company to explore the use of our exosome technology as a delivery vehicle for synthetic oligonucleotides used in gene therapy and is also in active discussions with other third parties regarding further potential collaborations.
In order to achieve these objectives, we work closely with a number of key academic and industrial partners while continuing to maintain tight control over our financial resources.
ReNeuron is incorporated in the UK with offices in the UK and the US. Our shares are traded on the London AIM market under the symbol RENE.L